Overview

2-Week Study In People With Nonalcoholic Fatty Liver Disease

Status:
Completed
Trial end date:
2019-04-04
Target enrollment:
Participant gender:
Summary
2-week study in people with nonalcoholic fatty liver disease. Study drug at 1 of 2 doses, or placebo, will be given for 14 days. Blood samples, heart monitoring, vital signs, and imaging procedures will be performed.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer